Sami Said, M.D. Training: Residency - Internal Medicine. University Hospital. Cairo, Egypt. NYU-Bellevue Medical Center. NY, NY. Fellowship - Cardiology, NYU-Bellevue Medic al Center. NY, NY. 1955-1957 Fellowship - Pulmonary, Johns Hopkins Medical School. Baltimore, MD. 1957-1958 Visiting Scientist, Karolinska Institute. Stockholm, Sweden. 1968-1970 Professional Appointments: Professor of Medicine, Physiology & Biophysics, SUNY-Stony Brook. Faculty member since 1991. Professor, Graduate Program in Pharmac ology, SUNY-Stony Brook. Assistant Chief of Staff, Research and Development, Northport VAMC. Interests: Acute lung injury (ARDS) with special reference to mechanisms and prevention; Cell injury/cell death; Asthma; Vasoactive Intestinal Peptide (VIP ) and related peptides. Alzheimer's disease; Teaching. Ongoing Research Projects: Apoptosis in acute lung injury Estrogen prot ection of the lung VIP and glutamate in airway inflammation and asthma Clinical trial of VIP in the Acute Respiratory Distress Sy ndrome (ARDS) E-mail: firstname.lastname@example.org Sami Said has published with his co-workers more than 370 scientific articles describing the biology of neurotransmitters, in particular that of the vasoactive intestinal peptide (VIP; A viptadil). His work wit h VIP began with its discovery, first in the lung and intestine, then in the brain and nerve cells. Research on VIP and related peptides has taken him and his colleagues on an exciting journey through many organ systems and across different disciplines, including physiology, pharmacology, biochemistry, endocrinology, and neuroscience. Prof. Said is Chairman of the National Organization for Rare Disorders (NORD) Medical Advisory Committee. NORD is a unique federation of voluntary health organizations in the United States dedicated to helping people with rare "orphan" diseases and assisting the organizations that serve them. NORD is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and service. Dr. Sami I. Said is appointed Distinguished Professor by the State University of New York for his seminal work on Vasoactive Intestinal Peptide (VIP; A vipt adil). The appointment was granted by the State University of New York Board of Trustees on November 28, 2006 for: "Your seminal work in the field of Medicine especially your groundbreaking scholars hip on the pharmacology of the Vasoactive Intestinal Peptide (V IP), a vasodilator new to science, was the impet us of your designation." Dr. Sami I. Said M. D. is professor in the departments of Medicine, Physiology, and Graduate Program in Pharmacology at Stony Brook University, and Faculty member since 1991. Born and educated in Cairo, Egypt, he moved to New York University Bellevue Medical Cent er for residency in internal medicine and a fellowship in Cardiology, followed by a fellowship in Pulmonary Physiology at Johns Hopkins Medical School. In 1969 together with Professor Viktor Mutt at Karolinska Institute in Stockholm Sweden he discovered VIP (A viptadil). His entire life since then has been dedicat ed to A vipt adil in rare diseases with emphasis on the respiratory system. Latest publications: Hamidi SA, Prabhakar S, Said SI. Enhancement of pulmonary vascular remodelling and inflammatory genes with VIP gene deletion. Eur Respir J. 2008 Jan;31(1):135-9. Said SI. The discovery of VIP: initially looked for in the lung, isolated from intestine, and identified as a neuropeptide. Peptides. 2007 Sep;28(9):1620-1. Said SI, Hamidi SA, Dickman KG, Szema AM, Lyubsky S, Lin RZ, Jiang YP, C hen JJ, Waschek JA, Kort S. Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation. 2007 Mar 13;115(10):1260-8. Hamidi SA, Szema AM, Lyubsky S, Dickman KG, Degene A, Mathew SM, Waschek JA, Said SI. Clues to VIP function from knockout mice. Ann N Y Acad Sci. 2006 Jul;1070:5-9. Szema AM, Hamidi SA, Lyubsky S, Dickman KG, Mathew S, Abdel-Razek T, Chen JJ, Waschek JA, Said SI. Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP. Am J Physiol Lung Cell Mol Physiol. 2006 Nov;291(5):L880-6. Said SI. Mediators and modulators of pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol. 2006 Oct;291(4):L547-58.
Pages to are hidden for
"Sami Said, M"Please download to view full document